The litigation centers on claims that Beta Bionics concealed critical issues surrounding its iLet device between July 30, 2025, and February 24, 2026. According to the complaint, the company failed to disclose an FDA Form 483 report, which documented over 18,000 complaints, including reports of life-threatening hypoglycemic events that allegedly went uninvestigated and unreported to federal regulators.

Beyond the safety failures, the suit contends that management downplayed the severity of FDA observations, characterizing them as benign while remediation efforts were significantly more complex than publicly stated. The complaint further alleges that the company opted against opening a corrective and preventive action (CAPA) process despite clear evidence of systemic issues, ultimately rendering their public statements on business prospects materially misleading.